RVMD vs. MRTX, KYMR, ARGX, BNTX, NBIX, QGEN, RGEN, PCVX, EXEL, and HALO
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Mirati Therapeutics (MRTX), Kymera Therapeutics (KYMR), argenx (ARGX), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector.
Revolution Medicines (NASDAQ:RVMD) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.
Mirati Therapeutics received 392 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 69.15% of users gave Revolution Medicines an outperform vote while only 64.82% of users gave Mirati Therapeutics an outperform vote.
Revolution Medicines has higher earnings, but lower revenue than Mirati Therapeutics. Revolution Medicines is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines has a net margin of 0.00% compared to Mirati Therapeutics' net margin of -1,900.65%. Revolution Medicines' return on equity of -36.41% beat Mirati Therapeutics' return on equity.
In the previous week, Revolution Medicines had 3 more articles in the media than Mirati Therapeutics. MarketBeat recorded 3 mentions for Revolution Medicines and 0 mentions for Mirati Therapeutics. Revolution Medicines' average media sentiment score of 1.14 beat Mirati Therapeutics' score of 0.00 indicating that Revolution Medicines is being referred to more favorably in the media.
Revolution Medicines presently has a consensus price target of $43.20, indicating a potential upside of 12.71%. Mirati Therapeutics has a consensus price target of $60.00, indicating a potential upside of 2.21%. Given Revolution Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Revolution Medicines is more favorable than Mirati Therapeutics.
Revolution Medicines has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
94.3% of Revolution Medicines shares are owned by institutional investors. 8.0% of Revolution Medicines shares are owned by company insiders. Comparatively, 3.3% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Revolution Medicines beats Mirati Therapeutics on 16 of the 19 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
